Journal of neurosurgery · 1996 · 337 citations · 45 references
MedicineAnesthesiologyPharmacotherapyAnesthesiaPain ManagementPain MedicineAnalgesiaAnalgesic PharmacologyImplantable Pain DevicesOpioid AnalgesicsOpioid TherapyPain OutcomesAnalgesic Efficacy AssessmentInfusion Pump SystemsInfusion Pump TherapyIntrathecal Drug Delivery SystemsIntrathecal Opioid TherapyIntrathecal OpioidsLong-term Side EffectsNeuropathic Pain Reduction
The study retrospectively evaluated the long‑term effects of continuous intrathecal opioid therapy delivered via implantable infusion pumps in 120 patients with chronic, nonmalignant pain syndromes. Patients were followed for 6 months to 5.7 years (mean 3.4 ± 1.3 years) in a retrospective design, assessing pain outcomes and opioid dosing. Deafferentation and neuropathic pain patients experienced the greatest benefit, with 68 % and 62 % visual‑analog‑scale pain reduction, and overall 74 % of the cohort reported significant pain relief (average 67 % at 6 months, 58 % at last follow‑up), high satisfaction (92 %) and quality‑of‑life improvement (81 %), though morphine doses rose on average from 2.7 to 4.7 mg/day over 3.4 years and tolerance required dose adjustments or pump removal in a minority.
✓ In the present retrospective investigation, the long-term effects of continuous intrathecal opioid therapy via implantable infusion pump systems were examined in 120 patients with chronic, nonmalignant pain syndromes. The follow-up period was 6 months to 5.7 years (mean 3.4 years ± 1.3 standard error of the mean). Deafferentation pain and neuropathic pain showed the best long-term results, with 68% and 62% pain reduction (visual analog scale), respectively. The mean morphine dosage initially administered was 2.7 mg/day (range 0.3–12 mg/day); after an average of 3.4 years, it was 4.7 mg/day (range 0.3–12 mg/day). In a long-term observation of 28 patients who received intrathecal morphine for longer than 4 years, 18 patients (64.3%) had a constant dosage history and 10 patients (35.7%) showed an increase in morphine dosage to more than ± mg/day 1 year after dosage determination. In seven cases, a tolerance developed; in four patients the tolerance was controlled by means of “drug holidays”; but in three patients it was necessary to remove the pump systems. Explantation of the pump system occurred in 22 additional cases for other reasons. Throughout the follow-up period, 74.2% of the patients profited from the intrathecal opiate therapy; the average pain reduction after 6 months was 67.4% and, as of the last follow-up examination, it was 58.1%. Ninety-two percent of the patients were satisfied with the therapy and 81% reported an improvement in their quality of life. The authors' 6-year experience with administration of intrathecal opioid medications for nonmalignant pain should encourage the use of this method in carefully selected patients.
45
The McGill Pain Questionnaire: Major properties and scoring methods
Ronald Melzack · Pain · 1975 · 6.9K citations
Nursing, Psychology, Pain Management +15
The validation of visual analogue scales as ratio scale measures for chronic and experimental pain
Donald D. Price, Patricia McGrath, Amir Rafii et al. · Pain · 1983 · 3.9K citations
Nursing, Psychology, Pain Medicine +16
The measurement of clinical pain intensity: a comparison of six methods
Mark P. Jensen, Paul Karoly, Sanford Braver · Pain · 1986 · 3.3K citations
Nursing, Psychology, Pain Medicine +14